中国肿瘤生物治疗杂志2024，Vol.31Issue(8)：752-758,7.DOI:10.3872/j.issn.1007-385x.2024.08.002
"载药囊泡化肿瘤靶向治疗术"临床应用专家共识
Expert consensus on clinical application of Drug-Loaded Microparticles Immunotherapy
摘要
Abstract
With the rapid development of precision medicine,extracellular vesicles(EVs)have shown tremendous potential in the diagnosis and therapeutic applications of diseases such as tumors.Drug-Loaded Microparticles Immunotherapy is an innovative cancer immunotherapy technology originating in China.It utilizes tumor-derived microparticles as carriers,encapsulating or loading commonly used clinical small molecule chemotherapeutic drugs.This approach achieves effective tumor destruction through mechanisms such as targeted drug delivery,activation of neutrophils,reversal of macrophages polarization,and enhancement of tumor antigen presentation.Over more than a decade of research into anti-tumor mechanisms,preclinical assessments,and clinical trials,this technology has successfully transitioned to clinical application and received clinical approval.To further advance the standardized and scientific application of Drug-Loaded Microparticles Immunotherapy,Committee for Tumor Immunology&Biotherapy of Chinese Society for Immunology and the Society of Cancer Biotherapy of China Anti-Cancer Association jointly organized technical and clinical experts in the fields of extracellular vesicles and tumor immunotherapy.After multiple rounds of discussions and revisions,they collaboratively drafted the"Expert Consensus on Clinical Application of Drug-Loaded Microparticles Immunotherapy".This consensus introduces the research and practical application of the therapy in cancer treatment,addresses existing challenges,and outlines future development directions.Its primary goal is to offer guidance and insights for the optimal clinical use of this innovative therapeutic approach.关键词
细胞外囊泡/肿瘤细胞来源的载药囊泡/肿瘤免疫治疗/恶性胸腹水/专家共识Key words
extracellular vesicle(EV)/tumor cell-derived drug-loaded microparticle/tumor immunotherapy/malignant pleural and abdominal effusion/expert consensus分类
医药卫生引用本文复制引用
中国免疫学会肿瘤免疫与生物治疗专业委员会,中国抗癌协会肿瘤生物治疗专业委员会,刘艳粉,秦国慧,王丹,黄波,张毅.."载药囊泡化肿瘤靶向治疗术"临床应用专家共识[J].中国肿瘤生物治疗杂志,2024,31(8):752-758,7.基金项目
国家重点研发计划(No.2022YFA1206000) （No.2022YFA1206000）
国家重点研发计划"政府间国际科技创新合作"项目(No.2022YFE0141000) （No.2022YFE0141000）
